Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.88%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.08 per share when it actually produced earnings of $0.16, delivering a surprise of +100%.Over the last four q ...

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +8.16%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.43 per share when it actually produced earnings of $0.08, delivering a surprise of -81.4%.Over the last fo ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Rigel Pharmaceuticals (RIGL) , which belongs to the Zacks Medical - Drugs industry, could be a great candidate to consider.This drug developer has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 197.73%.For the most recent quarter, Rigel was expect ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an e ...

Ardelyx (ARDX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than expectations. O ...

动量投资方法论 - 动量投资核心是追踪股票近期趋势 通过"买高卖更高"策略捕捉价格趋势延续性 [1] - 短期价格走势反映市场买卖力量对比 行业相对表现可筛选优质标的 [5] Soleno Therapeutics动量表现 - 公司获Zacks动量风格评分A级 Zacks综合评级为2级(买入) [3][4] - 过去一周股价上涨6.91% 显著跑赢医药-药品行业同期下跌0.38%的表现 [6] - 月度涨幅4.77%优于行业4.34% 季度涨幅17.34%及年度涨幅87.5%均大幅超越标普500指数 [6][7] - 20日平均成交量达1,461,273股 量价配合显示看涨信号 [8] 盈利预测修正 - 过去60天内3次上调全年盈利预测 共识预期从-3.09美元改善至-2.33美元 [10] - 下财年2次盈利预测上调 无下调修正 显示分析师信心持续增强 [10] 行业比较 - 医药-药品行业过去一周整体下跌0.38% 月度涨幅4.34%落后于公司表现 [6] - 标普500指数同期季度涨幅16.43% 年度涨幅18.63% 均显著低于公司涨幅 [7]

股价表现 - Stevanato Group (STVN) 股价在上一交易日大涨10%至27.95美元 成交量显著高于平均水平 [1] - 过去四周该股累计涨幅仅为0.6% 此次单日涨幅远超近期表现 [1] - 同行业公司BeOne Medicines Ltd (ONC) 同期上涨0.6%至296.46美元 过去一个月累计涨幅达10.4% [4] 业绩预期 - 公司预计季度每股收益0.11美元 同比增长10% 营收预期3.028亿美元 同比增长8.4% [3] - 过去30天共识EPS预测保持稳定 但缺乏盈利预测上修趋势可能限制股价持续上涨空间 [4] - 同业ONC的季度EPS预测过去一个月下调51.3%至0.48美元 但较去年同期仍增长141.7% [5] 增长驱动因素 - 高价值解决方案业务收入前景改善 特别是高端注射器需求强劲 [2] - Latina和Fishers生产基地产能提升 EZ-fill®西林瓶去库存周期结束带动需求反弹 [2] - 市场对收入持续增长预期增强 推动投资者信心回升 [2] 行业评级 - 公司当前获Zacks评级"买入"(Rank 2) 所属医疗-药品行业 [4] - 同业ONC当前评级为"持有"(Rank 3) [5]

Siga Technologies Inc. (SIGA) ended the recent trading session at $7.06, demonstrating a -1.4% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.07%. On the other hand, the Dow registered a loss of 0.7%, and the technology-centric Nasdaq increased by 0.18%. The stock of company has risen by 11.18% in the past month, leading the Medical sector's gain of 2.39% and the S&P 500's gain of 5.71%.The investment community will be paying close attention t ...

USANA Health Sciences (USNA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +37.04%. A quarter ago, it was expected that this nutritional supplement maker would post earnings of $0.7 per share when it actually produced earnings of $0.73, delivering a surprise of +4.29%.Over the last ...

股价表现 - Madrigal股价在上一交易日上涨10.9%至344.97美元，成交量显著高于平均水平[1] - 过去四周累计涨幅达11.3%，与单日涨幅相当[1] 专利进展 - 获得美国专利商标局关于Rezdiffra体重剂量方案的新专利授权，有效期至2044年[2] - 专利将被列入FDA橙皮书，预计通过阻止仿制药来增强市场独占性[2] - Rezdiffra作为首个获批的MASH疗法，截至2025年3月已有超过17,000名患者使用[2] 财务预期 - 预计季度亏损为每股3.64美元，同比改善48.7%[3] - 预计收入达1.6013亿美元，同比增长993.8%[3] - 过去30天共识EPS预期维持不变，缺乏修正趋势[4] 行业比较 - 同行业公司Corcept股价单日上涨2%至72.85美元，但过去一个月下跌0.6%[4] - Corcept预计EPS为0.23美元，同比下降28.1%，维持Zacks强卖评级[5]